InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,646.47
(
1.20%
)
Post# of 251711
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: kris_kade post# 203885

Monday, 08/29/2016 10:12:06 AM

Monday, August 29, 2016 10:12:06 AM

Post# of 251711
RVNC—We've had this discussion previously. RT001 didn't work for the simple reason that the toxin didn't get to where it was needed in sufficient quantity; this is the rationale that led me to predict more than a year ago that RT001 wouldn't work well in cosmetic indications (#msg-123277118).

I see no benefit to RVNC in releasing the full dataset from the RT001 study in crow's feet insofar as RVNC acknowledged that there was no separation between the RT001 and placebo arms.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up